Cargando…

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents....

Descripción completa

Detalles Bibliográficos
Autores principales:	Marathe, Chinmay S., Rayner, Christopher K., Jones, Karen L., Horowitz, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124003/ https://www.ncbi.nlm.nih.gov/pubmed/21747825 http://dx.doi.org/10.1155/2011/279530

Ejemplares similares

Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
por: Marathe, Chinmay S., et al.
Publicado: (2013)

Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes
por: Jalleh, Ryan J, et al.
Publicado: (2022)

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
por: Khoo, Joan, et al.
Publicado: (2009)

GLP-1R Signaling and Functional Molecules in Incretin Therapy
por: Wan, Wenwei, et al.
Publicado: (2023)

Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut–incretin axis response in healthy males
por: Wu, T, et al.
Publicado: (2015)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies : Are the GLP-1 therapies safe?
por: Butler, Peter C., et al.
Publicado: (2013)

A Biphasic Glucose Response during an Oral Glucose Tolerance Test Is Associated with Greater Plasma Insulin and GLP-1 Responses and a Reduction in 1-Hour Glucose but Does Not Relate to the Rate of Gastric Emptying in Healthy, Older Adults
por: Jalleh, Ryan J., et al.
Publicado: (2023)

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying
por: Marathe, Chinmay S., et al.
Publicado: (2022)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Ethnic disparities in insulin and glucose-dependent insulinotropic peptide (GIP) responses to intraduodenal glucose in health
por: Marathe, Chinmay S., et al.
Publicado: (2014)

Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control
por: Jalleh, Ryan J., et al.
Publicado: (2022)

Disparities in the Glycemic and Incretin Responses to Intraduodenal Glucose Infusion Between Healthy Young Men and Women
por: Xie, Cong, et al.
Publicado: (2023)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

Impact of gastric emptying to the glycemic and insulinemic responses to a 75‐g oral glucose load in older subjects with normal and impaired glucose tolerance
por: Trahair, Laurence G., et al.
Publicado: (2014)

Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes
por: Kamruzzaman, Md, et al.
Publicado: (2021)

Comparative effects of small intestinal glucose on blood pressure, heart rate, and noradrenaline responses in obese and healthy subjects
por: Trahair, Laurence G., et al.
Publicado: (2018)

Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance
por: Marathe, Chinmay S., et al.
Publicado: (2017)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Incretin-based therapies
por: Stonehouse, Anthony H, et al.
Publicado: (2012)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics
por: Wright, Shane C., et al.
Publicado: (2023)

Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
por: Borg, Malcolm J., et al.
Publicado: (2020)

Effects of Intraduodenal Glutamine on Incretin Hormone and Insulin Release, the Glycemic Response to an Intraduodenal Glucose Infusion, and Antropyloroduodenal Motility in Health and Type 2 Diabetes
por: Chang, Jessica, et al.
Publicado: (2013)

Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice
por: Arunachala Murthy, Tejaswini, et al.
Publicado: (2023)

Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes
por: Kang, Z. F., et al.
Publicado: (2012)

Pancreatitis Associated With Incretin-Based Therapies
por: Iyer, Shridhar N., et al.
Publicado: (2013)

Socioeconomic aspects of incretin-based therapy
por: Karagiannis, Thomas, et al.
Publicado: (2023)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
por: Malbert, Charles-Henri, et al.
Publicado: (2020)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE
por: LeValley, Stephanie L., et al.
Publicado: (2020)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
por: van Baar, Michaël J. B., et al.
Publicado: (2019)

Impact of Incretin-Based Therapies on Adipokines and Adiponectin
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
por: Borg, Malcolm J., et al.
Publicado: (2021)

Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine
por: Kaneto, Hideaki, et al.
Publicado: (2021)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
por: Chon, Suk, et al.
Publicado: (2016)

Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125
por: Bjerre Knudsen, Lotte, et al.
Publicado: (2013)

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
por: Moffett, R. Charlotte, et al.
Publicado: (2014)

Incretin-based therapies in 2021 – Current status and perspectives for the future
por: Rizzo, Manfredi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvdfv7701mm7oc9bk4rks2hoce